Skip to main content

Table 2 Early treatment response evaluation using mRECIST 4–12 weeks after initiation of treatment in all patients and by BCLC stage

From: Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy

Category

Response evaluation using mRECIST

ORR (%)

DCR (%)

CR

PR

SD

PD

ALL case (n = 61)

14

35

7

5

80.3

91.8

BCLC stage A/B (n = 22)

2

14

4

2

72.7

90.9

BCLC stage C (n = 39)

12

21

3

3

84.6

92.3

  1. Overall objective response rate (ORR) was defined as the percentage of patients with a best overall response of complete response (CR) or partial response (PR). Disease control rate (DCR) was defined as the percentage of patients with a best overall response of CR, PR, or stable disease (SD)
  2. CR = complete response; SD = stable disease; PR = partial response; PD = progressive disease
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us